Drug Profile
Research programme: DNA methyltransferase inhibitors - MGI Pharma
Alternative Names: DNA methyltransferase inhibitors research programme - MGI PharmaLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator MethylGene
- Developer MGI Pharma
- Class Small molecules
- Mechanism of Action DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 25 Mar 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 29 Jan 2008 MGI Pharma has been acquired by Eisai